Authors,Author(s) ID,Title,Year,Source tittle,Cited by,DOI,Country,Document Type,City,Access Type,aggregationType,EID
Kim S.,,Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer,2018,Nature Medicine,251,10.1038/s41591-018-0101-z,South Korea,Article,Suwon,0,Journal,2-s2.0-85049969565
Shitara K.,,"Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial",2018,The Lancet,281,10.1016/S0140-6736(18)31257-1,Japan,Article,Kashiwa,0,Journal,2-s2.0-85048592368
Yu P.,,Association between density of tumor-infiltrating lymphocytes and prognoses of patients with gastric cancer,2018,Medicine (United States),11,10.1097/MD.0000000000011387,China,Review,Nanning,1,Journal,2-s2.0-85049998859
Pagès F.,,International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study,2018,The Lancet,425,10.1016/S0140-6736(18)30789-X,France;France;France;France,Article,Paris;Paris;Paris;Paris,0,Journal,2-s2.0-85046846915
Fuchs C.S.,,Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 trial,2018,JAMA Oncology,411,10.1001/jamaoncol.2018.0013,United States,Article,New Haven,1,Journal,2-s2.0-85047499076
Lee C.K.,,Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: A systematic review and meta-analysis,2018,JAMA Oncology,141,10.1001/jamaoncol.2017.4427,Australia;Australia,Review,Sydney;Sydney,1,Journal,2-s2.0-85044550461
Harada K.,,Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma,2018,Gastric Cancer,29,10.1007/s10120-017-0760-3,United States,Article,Houston,1,Journal,2-s2.0-85027381382
Kang Y.K.,,"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial",2017,The Lancet,577,10.1016/S0140-6736(17)31827-5,South Korea,Article,Ulsan,0,Journal,2-s2.0-85030626436
Luksza M.,,A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy,2017,Nature,196,10.1038/nature24473,United States,Article,Princeton,0,Journal,2-s2.0-85034865728
Balachandran V.P.,,Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer,2017,Nature,291,10.1038/nature24462,United States,Article,New York,0,Journal,2-s2.0-85034815842
Li M.,,Should Nivolumab-Induced Colitis Be Treated by Infliximab?,2017,Clinical Gastroenterology and Hepatology,2,10.1016/j.cgh.2017.05.012,Netherlands,Letter,Rotterdam,1,Journal,2-s2.0-85021082092
Kawazoe A.,,"Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein–Barr virus status in a large cohort of gastric cancer patients",2017,Gastric Cancer,89,10.1007/s10120-016-0631-3,Japan;Japan,Article,Tokyo;Kashiwa,1,Journal,2-s2.0-84987648038
Rittmeyer A.,,"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial",2017,The Lancet,1768,10.1016/S0140-6736(16)32517-X,Germany,Article,Immenhausen,0,Journal,2-s2.0-85008239423
Kelly R.J.,,Immunotherapy for Esophageal and Gastric Cancer,2017,American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting,19,10.14694/EDBK_175231,United States,Review,Baltimore,0,Journal,2-s2.0-85042648691
Gibney G.,,Predictive biomarkers for checkpoint inhibitor-based immunotherapy,2016,The Lancet Oncology,469,10.1016/S1470-2045(16)30406-5,United States,Review,"Washington, D.C.",0,Journal,2-s2.0-85003475383
Reck M.,,Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer,2016,New England Journal of Medicine,3528,10.1056/NEJMoa1606774,Germany,Article,Grosshansdorf,1,Journal,2-s2.0-84994802263
Chen P.L.,,Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade,2016,Cancer Discovery,328,10.1158/2159-8290.CD-15-1545,United States,Article,Houston,1,Journal,2-s2.0-84982946696
Dong M.,,"Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in Epstein-Barr virus-associated gastric carcinoma",2016,Human Pathology,36,10.1016/j.humpath.2016.02.007,China,Article,Guangzhou,0,Journal,2-s2.0-84963791928
Muro K.,,"Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial",2016,The Lancet Oncology,511,10.1016/S1470-2045(16)00175-3,Japan,Article,Nagoya,0,Journal,2-s2.0-84964779633
Blank C.,,"The ""cancer immunogram""",2016,Science,323,10.1126/science.aaf2834,Netherlands,Review,Amsterdam,0,Journal,2-s2.0-84966309581
Fehrenbacher L.,,"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial",2016,The Lancet,1327,10.1016/S0140-6736(16)00587-0,United States,Article,CA,0,Journal,2-s2.0-84962038946
Topalian S.,,Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy,2016,Nature Reviews Cancer,922,10.1038/nrc.2016.36,United States,Review,Baltimore,0,Journal,2-s2.0-84963621254
Herbst R.S.,,"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial",2016,The Lancet,2837,10.1016/S0140-6736(15)01281-7,United States,Article,New Haven,0,Journal,2-s2.0-84950117835
Hugo W.,,Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma,2016,Cell,895,10.1016/j.cell.2016.02.065,United States;United States,Article,Los Angeles;Los Angeles,1,Journal,2-s2.0-84961221351
Thompson E.,,Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma,2016,Gut,177,10.1136/gutjnl-2015-310839,United States,Article,Baltimore,0,Journal,2-s2.0-84962150072
Derks S.,,Epithelial PD-L2 expression marks Barrett's esophagus and esophageal Adenocarcinoma,2015,Cancer Immunology Research,67,10.1158/2326-6066.CIR-15-0046,United States;Netherlands,Article,Boston;Amsterdam,1,Journal,2-s2.0-84962009435
Schadendorf D.,,Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma,2015,Journal of Clinical Oncology,1096,10.1200/JCO.2014.56.2736,Germany,Article,Essen,0,Journal,2-s2.0-84928917822
Garon E.B.,,Pembrolizumab for the treatment of non-small-cell lung cancer,2015,New England Journal of Medicine,2992,10.1056/NEJMoa1501824,United States,Article,Los Angeles,0,Journal,2-s2.0-84929481480
Rizvi N.A.,,Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer,2015,Science,3607,10.1126/science.aaa1348,United States;United States;United States,Article,New York;New York;New York,0,Journal,2-s2.0-84928761118
Woo S.R.,,Innate immune recognition of cancer,2015,Annual Review of Immunology,205,10.1146/annurev-immunol-032414-112043,United States,Article,Chicago,0,Book Series,2-s2.0-84927585373
Patel S.,,PD-L1 expression as a predictive biomarker in cancer immunotherapy,2015,Molecular Cancer Therapeutics,792,10.1158/1535-7163.MCT-14-0983,United States,Review,San Diego,1,Journal,2-s2.0-84935474357
Borghaei H.,,Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer,2015,New England Journal of Medicine,4456,10.1056/NEJMoa1507643,United States,Article,Philadelphia,1,Journal,2-s2.0-84944937210
Snyder A.,,Genetic basis for clinical response to CTLA-4 blockade in melanoma,2014,New England Journal of Medicine,2168,10.1056/NEJMoa1406498,United States,Article,New York,0,Journal,2-s2.0-84918828514
Tumeh P.C.,,PD-1 blockade induces responses by inhibiting adaptive immune resistance,2014,Nature,2802,10.1038/nature13954,United States;United States,Article,Los Angeles;Los Angeles,0,Journal,2-s2.0-84920956732
Bass A.J.,,Comprehensive molecular characterization of gastric adenocarcinoma,2014,Nature,2467,10.1038/nature13480,United States,Article,Boston,1,Journal,2-s2.0-84907270779
Sideras K.,,Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies,2014,Cancer Treatment Reviews,96,10.1016/j.ctrv.2013.11.005,Netherlands,Review,Rotterdam,0,Journal,2-s2.0-84896702241
Spranger S.,,"Up-regulation of PD-L1, IDO, and T<inf>regs</inf> in the melanoma tumor microenvironment is driven by CD8<sup>+</sup> T cells",2013,Science Translational Medicine,896,10.1126/scitranslmed.3006504,United States,Review,Chicago,0,Journal,2-s2.0-84883863501
Chen D.S.,,Oncology meets immunology: The cancer-immunity cycle,2013,Immunity,1842,10.1016/j.immuni.2013.07.012,United States;United States,Review,Stanford;San Francisco,1,Journal,2-s2.0-84880706152
Topalian S.,,"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer",2012,New England Journal of Medicine,7186,10.1056/NEJMoa1200690,United States,Article,Baltimore,0,Journal,2-s2.0-84862859820
Li Y.,,SOCS3 in immune regulation of inflammatory bowel disease and inflammatory bowel disease-related cancer,2012,Cytokine and Growth Factor Reviews,26,10.1016/j.cytogfr.2012.04.005,China;Netherlands,Review,Shanghai;Rotterdam,0,Journal,2-s2.0-84861660536
Van Hagen P.,,Preoperative chemoradiotherapy for esophageal or junctional cancer,2012,New England Journal of Medicine,2529,10.1056/NEJMoa1112088,Netherlands,Article,Rotterdam,0,Journal,2-s2.0-84861679981
Huh J.,,Prognostic significance of tumor-infiltrating lymphocytes for patients with colorectal cancer,2012,Archives of Surgery,88,10.1001/archsurg.2012.35,South Korea,Article,Gwangju,1,Journal,2-s2.0-84859993702
Pardoll D.,,The blockade of immune checkpoints in cancer immunotherapy,2012,Nature Reviews Cancer,5896,10.1038/nrc3239,United States,Review,Baltimore,0,Journal,2-s2.0-84858766182
Taube J.,,Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape,2012,Science Translational Medicine,1316,10.1126/scitranslmed.3003689,United States,Article,Baltimore,0,Journal,2-s2.0-84859128199
Hamid O.,,A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma,2011,Journal of Translational Medicine,350,10.1186/1479-5876-9-204,United States,Article,Santa Monica,1,Journal,2-s2.0-82155168544
Cunningham D.,,Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer,2006,New England Journal of Medicine,3760,10.1056/NEJMoa055531,United Kingdom;United Kingdom;United Kingdom,Article,London;London;Sutton,0,Journal,2-s2.0-33745726677
Peppelenbosch M.,,Macrophages present pinocytosed exogenous antigen via MHC class I whereas antigen ingested by receptor-mediated endocytosis is presented via MHC class II,2000,Journal of Immunology,14,10.4049/jimmunol.165.4.1984,Netherlands,Article,Amsterdam,1,Journal,2-s2.0-0034662981
